⌘K
Loading ticker…
As of 2026-08-24, Nektar Therapeutics (NKTR) has a 3-month relative strength percentile of 68 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 62. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.1%, relative volume 1.17×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
NKTR is in a stage 2 uptrend, week 5. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 5.8% / 14.9%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
NKTR is held by 9 ETFs as of May 2026. Top owner: SCHA at 0.04% weight, $10M notional. Top 3 carry $19M.
Held by 24 ETFs · $134M across latest filings · largest weight 3.14% (LFSC).
Top 9 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.04% | $10M | — |
| VHTVanguard Health Care ETF | 0.03% | $6M | — |
| LFSC | 3.14% | $3M | −0.47 pp |
| DWAS | 0.67% | $3M | new |
| SCHBSchwab U.S. Broad Market ETF | 0.00% | $1M | — |
| ONEQ | 0.00% | $448K | — |
| WSML | 0.02% | $122K | — |
| TMFX | 0.09% | $30K | +0.03 pp |
| AVTM | 0.00% | $1K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NKTR Jan avg: -1.60% median: -7.53% win: 25% σ: 15.05% n: 4 2022-04-12 → 2026-07-31 | NKTR Feb avg: 16.99% median: 16.23% win: 75% σ: 56.03% n: 4 2022-04-12 → 2026-07-31 | NKTR Mar avg: -8.06% median: -7.37% win: 50% σ: 34.28% n: 4 2022-04-12 → 2026-07-31 | NKTR Apr avg: 14.45% median: 16.98% win: 80% σ: 29.50% n: 5 2022-04-12 → 2026-07-31 | NKTR May avg: -16.86% median: -15.74% win: 0% σ: 6.37% n: 5 2022-04-12 → 2026-07-31 | NKTR Jun avg: 30.27% median: 7.60% win: 60% σ: 60.31% n: 5 2022-04-12 → 2026-07-31 | NKTR Jul avg: -1.89% median: 1.23% win: 60% σ: 9.65% n: 5 2022-04-12 → 2026-07-31 | NKTR Aug avg: 10.95% median: 5.27% win: 50% σ: 19.03% n: 4 2022-04-12 → 2026-07-31 (current) | NKTR Sep avg: 18.36% median: 0.83% win: 75% σ: 49.02% n: 4 2022-04-12 → 2026-07-31 | NKTR Oct avg: 0.47% median: 2.83% win: 50% σ: 18.51% n: 4 2022-04-12 → 2026-07-31 | NKTR Nov avg: -6.21% median: -1.88% win: 50% σ: 13.36% n: 4 2022-04-12 → 2026-07-31 | NKTR Dec avg: -14.39% median: -18.85% win: 25% σ: 21.24% n: 4 2022-04-12 → 2026-07-31 |